Identifying symptomatic adverse events using the patient‐reported outcomes version of the common terminology criteria for adverse events in patients with non‐small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations

OBJECTIVE: Tolerability and safety of treatments are important in oncology trials and should be informed by patient assessments. We identified the most relevant patient‐reported symptomatic adverse events (AEs) to measure in patients with non‐small cell lung cancer (NSCLC) with epidermal growth fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yanyan, Jean‐Baptiste, Milenka, Lenderking, William R., Bell, Jill A., Revicki, Dennis A., Lin, Huamao M., Brake, Rachael, Reeve, Bryce B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028096/
https://www.ncbi.nlm.nih.gov/pubmed/36583557
http://dx.doi.org/10.1002/cam4.5376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028096/
https://www.ncbi.nlm.nih.gov/pubmed/36583557
http://dx.doi.org/10.1002/cam4.5376

Ejemplares similares